Personalis Stock Jumps After Tempus AI Acquisition Deal And Q2 Beat

Personalis Inc. stocks have been trading up by 9.41 percent following bullish sentiment around its latest precision oncology advancements.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading PSNL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Q2 revenue came in at $22.4M, well ahead of the $16.7M consensus, signaling strong operating momentum before the Tempus deal.
Clinical testing volume for the NeXT Personal MRD test surged 199% year over year and 33% sequentially, with guidance for more than 500% clinical revenue growth this year.
Tempus AI agreed to acquire Personalis for $16.25 per share under a flexible mix of stock and possible cash, creating a clear deal anchor for PSNL.
Several shareholder-rights and class-action firms are challenging whether the $16.25 Tempus offer undervalues Personalis, keeping open the door for noise around price and process.
With the Tempus merger pending, management will no longer issue guidance or hold earnings calls, shifting trader focus from quarterly performance to deal odds and timing.

Weekly Update Aug 17 – Aug 21, 2026: On Sunday, August 23, 2026 Personalis Inc. stock [NASDAQ: PSNL] is trending up by 9.41%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Personalis sits in a strong strategic niche in oncology MRD testing but remains fundamentally loss-making, with EBIT margin at roughly –154% and ROE near –50%. Q2 revenue of $22.4M and gross margin above 60% confirm attractive unit economics but subscale operations. Cash of ~$94M and current ratio of 5.3 provide a multi‑year runway despite negative free cash flow (~$30M). At ~28x sales and ~8x book, equity is already discounting the Tempus takeout and robust growth.

Technically, PSNL has transitioned from a consolidation base to a sharp breakout: the weekly sequence from $13.77 to $18.47 reflects a strong, accelerating uptrend with increasingly higher closes and no meaningful pullbacks. The rapid move above the $16.25 deal reference and through $18 highlights speculative positioning on a higher bid or deal risk. For trading, $16.25 is the critical downside level; a sustained break back below that should trigger exits, while dips toward $17–17.50 are the only justifiable risk‑managed entries.

More Breaking News

The announced Tempus AI acquisition at $16.25 per share effectively caps standalone valuation in the near term, but current trading well above the offer signals the market is pricing in either a bump in consideration or deal disruption. Compared with healthcare and diagnostics peers, PSNL offers superior growth but far weaker profitability, justifying a takeout rather than independent re‑rating. Base case is deal closure; upside comes only from a revised bid. Near‑term trading range: support $16.25, resistance $20, tactical target $19.

Quick Financial Overview

Personalis Inc. has moved from a pure growth story to an M&A-driven trade, but the underlying numbers still matter. Q2 revenue of $22.4M beat the $16.7M consensus by a wide margin, backed by a sharp ramp in NeXT Personal MRD volumes. That kind of beat supports the argument that PSNL is being bought from a position of strength, not distress, and it underpins the $16.25 per-share takeout level as a key reference point.

At the same time, the core business is still loss-making. Recent income statement data show total revenue of about $22.4M against total expenses of roughly $55.9M for the quarter, producing a net loss of about $31.7M and EBITDA near -$29.2M. Margins are deeply negative, with profit margin metrics around -150%, but gross margin of 63.3% shows strong unit economics once scale improves. Cash flow from operations was roughly -$25.8M, yet the company finished the quarter with about $95.8M in cash and a current ratio of 5.3, giving Personalis room to fund operations into the Tempus close.

On the trading side, PSNL has already repriced toward the deal zone. Weekly data show the stock lifting from the mid-teens to close near $18.47, above the announced $16.25 consideration, which often signals the market is either pricing in the value of Tempus stock in the mix or a small chance of a sweetened bid. Intraday, a sharp spike from roughly $16.65 to an $18.89 high before settling near $18.38 highlights aggressive, event-driven buying and profit taking. For short-term traders, that creates a band where the $16.25 deal price is the downside anchor and the mid-to-high $18 area reflects current optimism and merger-arb positioning.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!